Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
Bausch + Lomb (BLCO) reported Q3 2026 revenue of $1.375B, up 7% YoY. GAAP net income was $32M, and adjusted EBITDA reached $325M. The company raised its full-year 2026 guidance. Key products like MIEBO, LUMIFY, and premium IOLs drove growth across segments.
How this was made
The 30-second read
Why it matters
Q3 showed broad revenue growth and improved profitability, and the company raised full-year 2026 revenue and adjusted EBITDA excluding acquired IPR&D, which can drive near-term earnings estimate revisions and sentiment in eye-health equities.
Market read
Traders can update BLCO valuation and positioning based on the guidance raise and the demonstrated operating leverage in Q3.
What to watch
The article provides segment growth drivers (MIEBO, LUMIFY, premium IOL) but does not quantify margins by segment or detail competitive/price dynamics, which could temper how durable the guidance raise is.
Background
Bausch + Lomb (BLCO) released its Q3 2026 financial results and updated full-year 2026 guidance, citing growth across Vision Care, Surgical, and Pharmaceuticals.
Ticker impact
Bausch + Lomb reported Q3 2026 revenue of $1.375B and raised full-year 2026 revenue and adjusted EBITDA guidance.
Likely upward pressure as the market digests the guidance raise and improved operating leverage.
The article is a primary earnings release with explicit Q3 results and an updated full-year outlook, which typically drives near-term estimate revisions.
Market effects
Positive read-through for eye-health and specialty pharma demand signals, especially contact lenses and surgical IOL growth.
Limited direct regional impact indicated; results are global with only minor FX headwind noted.
Moderate, as it is company-specific rather than a macro or sector-wide policy catalyst.
Counterpoint
Guidance is non-GAAP and the release highlights constant-currency growth, so reported results could be more sensitive to FX and non-recurring items than the headline implies.
Key entities
- companyBausch + Lomb Corporation
Eye-health company reporting Q3 2026 results and raising full-year 2026 guidance.
- productMIEBO
Reported revenue grew 42% to $119M in Q3 2026.
- productLUMIFY
Reported revenue grew 35% in Q3 2026.
- product portfolioPremium IOL
Reported revenue grew approximately 70% in Q3 2026.
